The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Ethakota, J. , Singh, B. , Bai, S. , Tareen, H. , Kumar, D. and Malik, D. (2025) The Role of Artificial Intelligence in ...

After last week’s essay about this disease condition, it has become necessary to help readers understand the peculiar nature of the organ.

Globally, pancreatic cancer ranks 12th in terms of incidence but sixth for mortality signifying its aggressive behavior and limited treatment options. While the mortality rates for many other solid ...

The gut microbiome has emerged as a potential factor in cancer pathogenesis, but its role in non-functioning pituitary neuroendocrine tumors (NF-PitNETs) remains unclear. This study aimed to elucidate ...

well-differentiated pancreatic neuroendocrine tumors (pNET) and extrapancreatic NET (epNET). Specifically, the approval is for those with unresectable, locally advanced, or metastatic pNET and ...

The FDA has ap­proved Ex­elix­is’ can­cer drug Cabome­tyx to treat ad­vanced neu­roen­docrine tu­mors in­side and out­side of the pan­creas, mark­ing two new in­di­ca­tions for ...

well-differentiated pancreatic or extra-pancreatic neuroendocrine tumors (pNET or epNET), the FDA said Wednesday. In an interesting and unusual item in Cabometyx’s updated label, the FDA ...

In January 2025, the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Neuroendocrine and Adrenal Tumors were updated to include cabozantinib as a category 1 ...

Cabometyx is approved for treating well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors in patients 12 years and older. The phase 3 CABINET trial showed improved progression-free ...

Cabozantinib significantly delayed disease progression in advanced pancreatic and extra-pancreatic neuroendocrine tumors, as shown in the phase 3 CABINET trial. The trial demonstrated a median PFS ...